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(OR:1.16; CI:1.03–1.31), and 2 (OR:1.47; CI:1.30–1.65)]. Findings were similar
when stratifying the sample by age group. CONCLUSIONS: Findings suggest that a 
quarterly assessment of SABA utilization can be used to identify patients at risk for
asthma-related exacerbations. The incidence of an asthma exacerbation was associated
with greater SABA use in the previous quarter.
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OBJECTIVES: Comorbidities in patients with chronic obstructive pulmonary disease
(COPD) are associated with higher mortality, hospitalization, and poor quality of life. 
The objectives of this study were to characterize a comprehensive comorbidity proﬁ le 
among COPD patients, and to explore the impact of comorbidities on medical utiliza-
tion and cost in a low-income Medicaid population. METHODS: This retrospective 
cohort study analyzed medical claims from the Maryland Medicaid database. We
employed a 1:2 case-control design to select 1388 COPD patients aged 40 to 64 years 
with at least 24 months of continuous enrollment and 2776 demographically-matched
controls without COPD. Logistic regressions were performed to calculate odds ratios
that compared differences in the prevalence of comorbidities, including 17 conditions
deﬁ ned by the Charlson Comorbidity Index (CCI) and 6 additional conditions known 
to coexist with COPD. Generalized linear models were performed to estimate the
average medical utilization and cost by speciﬁ c comorbidity. RESULTS: Medicaid 
COPD patients had more comorbidities compared with non-COPD controls (CCI 
score  1.56 vs. 1.37, p  0.004), and were more likely to have myocardial infarction,
congestive heart failure, cerebrovascular disease, peptic ulcer, mild liver disease, hyper-
tension, sleep apnea, tobacco use, and edema. COPD patients on average had 16 more 
medical claims (81.4 vs. 65.4, p  0.001) and incurred $1871 higher medical cost per
year than non-COPD controls ($7603 vs. $5732, p  0.001). Ten out of the 17 condi-
tions deﬁ ned by the CCI as well as hypertension, tobacco use, and edema were associ-
ated with the excess medical utilization and cost in COPD patients. Depression was
associated with excess medical utilization but not cost. CONCLUSIONS: Medicaid
COPD patients have a substantial burden of comorbidities, which translate into higher
medical utilization and cost. Effective disease management and treatment protocols
are needed to reduce co-morbidity burden.
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OBJECTIVES: To assess real-world effectiveness of BUD/FM DPI versus tiotropium
DPI in COPD patients METHODS: Data from the Quebec health care databases
were used to construct a matched cohort of COPD patients aged d40 years newly
treated with BUD/FM DPI or tiotropium DPI from 2003–2007. Patients were matched 
on age, sex, COPD exacerbations (short-course prescription of oral corticosteroids
[OCSs], emergency department [ED] visits or hospitalizations for COPD; d2 events
occurring within 15 days counted as 1 exacerbation), and use of short-acting
inhaled a]2-agonists (SABAs) and ipratropium in the year before therapy began. 
The number of exacerbations, ED visits, and hospitalizations for COPD; claims
for OCS prescriptions; and the average weekly doses (dose  2 inhalations) of 
SABAs and ipratropium were compared for BUD/FM DPI versus tiotropium DPI 
users for a 1-year post-therapy period. Poisson and linear regression models were used
to produce adjusted rate ratios (RR) and mean differences (MD). RESULTS: Of 
981 BUD/FM DPI and 981 tiotropium DPI users in the cohort, 78% were aged „d 
65 years and 53% were men. No signiﬁ cant differences were seen for COPD exacerba-
tions (RR  0.94; 95% CI, 0.77–1.15), ED visits for COPD (RR  0.80; 95% CI,
0.54–1.20), and claims for OCS prescriptions (RR  0.93; 95% CI, 0.72–1.21) 
between BUD/FM DPI and tiotropium DPI users in the year after the start of 
therapy. However, BUD/FM DPI users had signiﬁ cantly fewer hospitalizations for
COPD (RR  0.65; 95% CI, 0.44–0.97), used less SABAs (MD  0.48; 95% CI,
0.67 to 0.28), and used more ipratropium (MD  0.35; 95% CI, 0.21–0.50).
CONCLUSIONS: These ﬁ ndings showed that patients using BUD/FM DPI were sig-
niﬁ cantly less likely to have COPD exacerbations leading to a hospitalization, but as 
likely as tiotropium DPI users to require emergency care or OCS therapy in the year 
after initiation of therapy.
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OBJECTIVES: To date, there is mixed evidence on the safety and effectiveness of 
tiotropium. Our objective was to evaluate the comparative effectiveness of regimens
containing tiotropium versus other medication regimens for chronic obstructive pul-
monary disease (COPD) in real-world clinical settings. METHODS: We conducted a 
cohort study on two separate cohorts with a diagnosis of COPD in the VA health care 
system. Patients with a COPD diagnosis prescribed tiotropium and patients in a his-
toric cohort prior to the introduction of tiotropium were selected for comparison using
propensity scores, with the base case including scores from 0.1 to 0.4. Outcomes
identiﬁ ed during follow-up were all-cause mortality, COPD exacerbations, and
COPD hospitalizations. Exposure to COPD medication regimens was deﬁ ned in a
time-varying manner and Cox proportional hazards regression were employed to
evaluate outcomes. RESULTS: For 42,090 patients in the base case, the regimen of 
tiotropium plus inhaled corticosteroids plus long-acting beta-agonists was associated 
with 40% reduced risk of death (HR  0.60 [95% CI 0.45, 0.79]) compared to inhaled
corticosteroids plus long-acting beta-agonists. This combination was also associated 
with reduced rates of COPD exacerbations (HR  0.84 [0.73, 0.97]) and COPD hos-
pitalizations (HR  0.78 [0.62, 0.98]). Tiotropium in combination with other medica-
tion regimens was associated with increased risk of events compared to inhaled 
corticosteroids plus long-acting beta-agonists. CONCLUSIONS: When used with 
inhaled corticosteroids and long-acting beta-agonists, tiotropium use was associated 
with a decreased risk of mortality compared to treatment with inhaled corticosteroids
and long-acting beta-agonists. However, this result was not consistent in other medica-
tion regimens that included tiotropium.
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OBJECTIVES: To identify subgroups of metabolic syndrome patients who would
be more homogeneous in terms of metabolic risk factors. METHODS: The 
electronic medical record database from GE Healthcare was used for this study. The 
database comprises de-identiﬁ ed longitudinal medical records of nationally repre-
sentative patients attending general practitioners. All adult patients were assessed 
for the presence of metabolic syndrome using the guidelines proposed by the 
National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). 
A latent class analysis was conducted based on the abnormality of patients’ metabolic 
risk factors including triglycerides (TG; q150 mg/dL), high-density lipoprotein 
cholesterol (HDL-C; men: 40 mg/dL; women: 50 mg/dL), blood pressure (BP; sys-
tolic q130 mmHg, diastolic q85 mmHg, or drug treatment for hypertension), fasting
plasma glucose (q100 mg/dL or drug treatment for diabetes mellitus), and waist cir-
cumference (WC; men: q102 cm; women: q88 cm). The ﬁ nal model was selected based 
on model ﬁ t indices including Akaike’s information criterion, Bayesian information 
criterion (BIC), and sample-size adjusted BIC. RESULTS: Metabolic syndrome was 
present in 19,251 individuals. The prevalence of high blood pressure was 96.4%. All 
the ﬁ t indices in the LCA modeling pointed to a 5-class solution. In addition to high 
blood pressure, members of Class 1 (6.5%) had abnormal TG and HDL-C; members 
of Class 2 (4.6%) had abnormal HDL-C and WC; members of Class 3 (19.7%) had 
abnormal TG and WC and the majority also had abnormal HDL-C (probability: 
68.7%); members of Class 4 (8.2%) had abnormal plasma glucose and WC; and
members of Class 5 (61.1%) had high probability of abnormality in all metabolic risk 
factors (range: 79.9–100%). CONCLUSIONS: LCA represents a new method for 
casemix study of patients with metabolic syndrome. The subgroups of metabolic syn-
drome identiﬁ ed in this study need to be further studied for its usefulness in clinical
and health services research.
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Longitudinal clinical trial data present analysts with the unique challenge of summariz-
ing large trends over time without losing the detail of changes from one timepoint 
to the next. Analysts must ﬁ nd a balance between the preservation of details at
each timepoint and parsimonious output that can be easily summarized and inter-
preted. For instruments that measure outcomes using nominal or ordinal response 
categories, analysts may want to preserve categorical information by reporting
response category frequencies over time. In this case, the frequency of change across
the course of treatment or disease progression is more informative, and perhaps more
appropriate, than mean or median change. Collapsing responses into mean or medians 
draws attention to overall trends, while losing the ability to detect movement from
one category response to another. A novel data visualization solution, stacked cumula-
tive percent plots, allows analysts to retain individual categorical responses and 
track the movement of categorical responses over time. Comparisons of stacked 
cumulative percent plots with mean plots illustrate the additional information that 
can be learned from retaining categorical information. Further, a variation of the 
proposed plot allows analysts to visualize the frequency of response category changes 
